Metabolic disorders detectable by tandem mass spectrometry and unexpected early childhood mortality: A population-based study

American Journal of Medical Genetics

Volumn 140 A, Issue 8, 2006, Pages 837-842

  Dott, Mary ^a,b   Chace, Donald ^c   Fierro, Marcella ^d,e   Kalas, Theodore A ^c   Hannon, W Harry ^f   Williams, Jennifer ^a,b   Rasmussen, Sonja A ^a,b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c PERKINELMER INC   (United States)

^d VIRGINIA DEPARTMENT OF HEALTH   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^f NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

Author keywords

Medical examiner; Metabolic disorder; Mortality; Newborn screening; Tandem mass spectrometry

Indexed keywords

DNA;

ACIDEMIA; ARTICLE; AUTOPSY; CAUSE OF DEATH; CHILDHOOD MORTALITY; DNA DETERMINATION; FATTY ACID OXIDATION; HUMAN; INFANT; LABORATORY TEST; METABOLIC DISORDER; POPULATION RESEARCH; PRESCHOOL CHILD; PRIORITY JOURNAL; SCREENING; SIBLING; TANDEM MASS SPECTROMETRY;

ACYL-COA DEHYDROGENASE; CHILD, PRESCHOOL; DEATH, SUDDEN; HUMANS; INFANT; INFANT, NEWBORN; METABOLIC DISEASES; TANDEM MASS SPECTROMETRY;

EID: 33645556518     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.31180     Document Type: Article

References (29)

1. Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, Frazier DM, Udvari S, Bross P, Knudsen I, Banas R, Chace DH, Engel P, Naylor EW, Gregersen N. 2001. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: Identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68:1408-1418.
2. Arens R, Gozal D, Jain K, Muscati S, Heuser ET, Williams JC, Keens TG, Ward SL. 1993. Prevalence of medium-chain acyl-coenzyme A dehydrogenase deficiency in the sudden infant death syndrome. J Pediatr 122:715-718.
3. Bennett MJ, Powell S. 1994. Metabolic disease and sudden, unexpected death in infancy. Hum Pathol 25:742-746.
4. Bennett MJ, Spotswood SD, Ross KF, Comfort S, Koonce R, Boriack RL, Ijlst L, Wanders RJ. 1999. Fatal hepatic short-chain L-3-hydroxyacyl-coenzyme A dehydrogenase deficiency: Clinical, biochemical, and pathological studies on three subjects with this recently identified disorder of mitochondrial beta-oxidation. Pediatr Dev Pathol 2:337-345.
5. Boles RG, Buck EA, Blitzer MG, Platt MS, Cowan TM, Spencer K, Yoon H, Madsen J, Reyes-Mugica M, Rinaldo P. 1998. Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. J Pediatr 132:924-933.
6. CDC. 2001. Using tandem mass spectrometry for metabolic disease screening among newborns. A report of a working group. MMWR 50:1-23.
7. CDC. 2003a. Contribution of selected metabolic diseases to early childhood deaths-Virginia, 1996-2001. MMWR 52:677-679
8. [reprinted 2003. JAMA 290:881-882].
9. CDC. 2003b. Death investigation system descriptions [online]. Available at: http://www.cdc.gov/epo/dphsi/mecisp/virginia.htm. Accessed February 14, 2003.
10. Chace DH, DiPerna JC, Mitchell BL, Sgroi B, Hofman LF, Naylor EW. 2001. Electrospray tandem mass spectrometry for analysis of acylcarnitines in dried postmortem blood specimens collected at autopsy from infants with unexplained cause of death. Clin Chem 47:1166-1182.
11. Dundar M, Lanyon WG, Connor JM. 1993. Scottish frequency of the common G985 mutation in the medium-chain acyl-CoA dehydrogenase (MCAD) gene and the role of MCAD deficiency in sudden infant death syndrome (SIDS). J Inherit Metab Dis 16:991-993.
12. Ensenauer R, Vockley J, Willard JM, Huey JC, Sass JO, Edland SD, Burton BK, Berry SA, Santer R, Grunert S, Koch HG, Marquardt I, Rinaldo P, Hahn S, Matern D. 2004. A common mutation is associated with a mild, potentially asymptomatic phenotype in patients with isovaleric acidemia diagnosed by newborn screening. Am J Hum Genet 75:1136-1142.
13. GeneTests. 2005. Medical Genetics Information Resource (online). Copyright, University of Washington and Children's Health System, Seattle. 1993-2005. Updated weekly. Available at http://www.genetests.org. Accessed January 25, 2005.
14. Goodman SI, Frerman FE. 2001. Organic Acidemias due to defects in lysine oxidation:2-ketoadipic acidemia and glutaric acidemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 8th edition. NewYork: McGraw-Hill. p 2195-2204.
15. Iafolla AK, Thompson RJ Jr, Roe CR. 1994. Medium-chain acyl-coenzyme A dehydrogenase deficiency: Clinical course in 120 affected children. J Pediatr 124:409-415.
16. Insigna RP, Laessig RH, Hoffman GL. 2002. Newborn screening with tandem mass spectrometry: Examining its cost-effectiveness in the Wisconsin newborn screening panel. J Pediatr 141:524-531.
17. Lundemose JB, Kolvraa S, Gregersen N, Christensen E, Gregersen M. 1997. Fatty acid oxidation disorders as primary cause of sudden and unexpected death in infants and young children: An investigation performed on cultured fibroblasts from 79 children who died aged between 0-4 years. Mol Pathol 50:212-217.
18. NNSGRC. 2005. U.S. National Screening Staats Report-MS/MS. Updated 4/13/2005. (online) Available at: http://genes-rus.uthscsa.edu/nbsdisorders.pdf. Accessed April 15, 2005.
19. Pourfarzam M. Morris A, Appleton M, Craft A, Bartlett K. 2001. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 358:1063-1064.
20. Roe CR, Ding J. 2001. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS. Valle D, editors. The metabolic and molecular basis of inherited disease. 8th edition. NewYork: McGraw-Hill. p 2297-2326.
21. Schoen FJ, Baker JC, Colby CJ, To TT. 2002. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics 110:781-786.
22. Sweetman L, Williams JC. 2001. Branched chain organic acidurias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 8th edition. NewYork: McGraw-Hill. p 2125-2163.
23. Tourna EH, Charpentier C. 1992. Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child 67:142-145.
24. Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, Eaton RB, Greenstein R, Korson M, Larson C, Marsden D, Msall M, Naylor EW, Pueschel S, Seashore M, Shih VE, Levy HL. 2003. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290:25642572.
25. Wang SS, Fernhoff PM, Khoury MJ. 2000. Is the G985A allelic variant of medium-chain acyl-CoA dehydrogenase a risk factor for sudden infant death syndrome? A pooled analysis. Pediatrics 105:1175-1176.
26. Wilcken B, Hammond J, Silink M. 1994. Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 70:410-412.
27. Wilcox RL, Nelson CC, Stenzel P, Steiner RD. 2002. Postmortem screening for fatty acid oxidation disorders by analysis of Guthrie cards with tandem mass spectrometry in sudden unexpected death in infancy. J Pediatr 141:833-836.
28. Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. 1999- Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child 80:459-462.
29. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, Strauss AW, Comeau AM, Eaton RB, Grady GF. 2001. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: A two-year summary from the New England newborn screening program.[comment]. Clin Chem 47:1945-1955.